Actively Recruiting
TAVR for Aortic Valve Disease
Led by Nanjing First Hospital, Nanjing Medical University · Updated on 2024-11-15
5000
Participants Needed
1
Research Sites
808 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Transcatheter aortic valve replacement (TAVR) has became an important treatment of severe aortic stenosis (AS). Several randomized clinical trials showed that TAVR was non-inferior or superior to surgical aortic valve replacement (SAVR). However, many different issues have emerged: TAVR in younger patients? valve leaflet thrombosis? transcatheter valve durability? coronary reaccess after TAVR? TAVR in bicuspid aortic valve? TAVR in aortic regurgitation? etc. Hence, a prospective, multicenter database is created to provide the real-word data for these questions.
CONDITIONS
Official Title
TAVR for Aortic Valve Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Clinical diagnosis of severe aortic stenosis or aortic regurgitation
- Patients undergo transcatheter aortic valve replacement
You will not qualify if you...
- Patients refuse the clinical follow-up
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Nanjing First Hospital
Nanjing, Jiangsu, China, 210006
Actively Recruiting
Research Team
J
Jun-Jie Zhang, MD
CONTACT
J
Jing Kan, MPH
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here